Answers are grounded in this paper and cite their sources.
Analysis of registry records reveals over 99% reliance on costly potassium citrate for nephrolithiasis, highlighting annual savings up to $23.6 million with alternative alkalinizing agents.
You have accessJournal of UrologyStone Disease: Medical & Dietary Therapy (MP26)1 May 2024MP26-10 TRENDS IN USAGE AND COST OF POTASSIUM CITRATE AND ALTERNATIVE ALKALINIZING AGENTS FOR NEPHROLITHIASIS Jake Drobner, Kevin J. Chua, Benjamin Lichtbroun, John Pfail, and Ji Hae Park Jake DrobnerJake Drobner , Kevin J. ChuaKevin J. Chua , Benjamin LichtbrounBenjamin Lichtbroun , John PfailJohn Pfail , and Ji Hae ParkJi Hae Park View All Author Informationhttps://doi.org/10.1097/01.JU.0001009408.66023.77.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The rising incidence of nephrolithiasis places a hefty financial burden on the United States healthcare system. Potassium citrate, a mainstay in the medical management of nephrolithiasis, is cost-prohibitive for patients and further exacerbates this burden. Alternative alkalinizing agents have demonstrated similar efficacy and are less expensive. This study aims to examine urologists' prescribing patterns for alkalinizing agents over time. METHODS: The Medicare Part D Prescribers Database was used to identify prescriptions specifically by urologists for alkalinizing agents including potassium citrate, potassium bicarbonate, sodium citrate, and sodium bicarbonate. The total annual expenditure, number of claims, and cost per claim from 2013 to 2020 were calculated and analyzed. RESULTS: Potassium citrate represented>99% of claims and costs each year for alkalinizing agents. Expenditure for potassium citrate increased from $13,711,645.99 in 2013 to $27,189.128.66 in 2020 (Table 1). Claims for potassium citrate also increased from 97,734 in 2013 to 152,450 in 2020. The percentage of branded potassium citrate prescribed, which was $49.49–$170.80 more expensive per claim than the generic version, declined from 2.23% in 2013 to 0.02% in 2020. The yearly cost per claim was $140.30–$209.37, $27.00–$47.35, $18.17–$42.69, and $21.75–$70.56 for potassium citrate, potassium bicarbonate, sodium citrate, and sodium bicarbonate, respectively. Potassium citrate was $118.54–$155.04 more expensive per claim than the next most expensive alternative and $122.09–$185.84 more expensive per claim than the cheapest alternative. Prescribing the next most expensive alternative instead of potassium citrate would have resulted in cost savings ranging from $11,585,492.14–$23,573,029.70 per year. CONCLUSIONS: Urologists can generate significant cost savings by prescribing alternative alkalinizing agents. Lowering the cost of alkali therapy is essential to reducing financial toxicity for patients and improving equitable access to preventative stone treatment. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e417 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Jake Drobner More articles by this author Kevin J. Chua More articles by this author Benjamin Lichtbroun More articles by this author John Pfail More articles by this author Ji Hae Park More articles by this author Expand All Advertisement PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Drobner et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: